EA200200182A1 - Способ отрицательной регуляции активности gdf-8 - Google Patents

Способ отрицательной регуляции активности gdf-8

Info

Publication number
EA200200182A1
EA200200182A1 EA200200182A EA200200182A EA200200182A1 EA 200200182 A1 EA200200182 A1 EA 200200182A1 EA 200200182 A EA200200182 A EA 200200182A EA 200200182 A EA200200182 A EA 200200182A EA 200200182 A1 EA200200182 A1 EA 200200182A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gdf
methods
vaccination
homologous
pharmaceutical compositions
Prior art date
Application number
EA200200182A
Other languages
English (en)
Other versions
EA005248B1 (ru
Inventor
Торбен Халькиер
Серен Моуритсен
Стеен Клюснер
Original Assignee
Фармекса А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармекса А/С filed Critical Фармекса А/С
Publication of EA200200182A1 publication Critical patent/EA200200182A1/ru
Publication of EA005248B1 publication Critical patent/EA005248B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)

Abstract

Описаны новые способы увеличения мышечной массы путем иммунизации животных против фактора дифференцировки роста 8 (GDF-8, миостатин). Иммунизацию предпочтительно осуществляют путем введения аналогов GDF-8, способных индуцировать вырабатывание антител против гомологичного GDF-8. Особенно предпочтительным иммуногеном является гомологичный GDF-8, который был модифицирован путем введения одного или нескольких чужеродных иммунодоминантных и смешанных Т-клеточных эпитопов, которые, в основном, сохраняют третичную структуру гомологичного GDF-8. Описана также вакцинация нуклеиновыми кислотами против GDF-8 и вакцинация с использованием живых вакцин, а также способы и средства осуществления такой вакцинации. Такими способами и средствами являются способы идентификации эффективных иммуногенных аналогов GDF-8, способы получения аналогов и фармацевтических композиций, а также фрагменты нуклеиновых кислот, векторы, трансформированные клетки, полипептиды и фармацевтические композиции.Отчет о международном поиске был опубликован 2001.07.19.
EA200200182A 1999-07-20 2000-07-20 Способ отрицательной регуляции активности gdf-8 EA005248B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26
PCT/DK2000/000413 WO2001005820A2 (en) 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity

Publications (2)

Publication Number Publication Date
EA200200182A1 true EA200200182A1 (ru) 2002-06-27
EA005248B1 EA005248B1 (ru) 2004-12-30

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200182A EA005248B1 (ru) 1999-07-20 2000-07-20 Способ отрицательной регуляции активности gdf-8

Country Status (21)

Country Link
US (2) US7070784B1 (ru)
EP (1) EP1200119A2 (ru)
JP (1) JP2003506325A (ru)
KR (1) KR100750695B1 (ru)
CN (1) CN1384757A (ru)
AU (1) AU778470B2 (ru)
CA (1) CA2379852A1 (ru)
EA (1) EA005248B1 (ru)
EE (1) EE200200025A (ru)
HK (1) HK1048937A1 (ru)
HR (1) HRP20010900A2 (ru)
HU (1) HUP0201861A3 (ru)
IL (1) IL146845A0 (ru)
MX (1) MXPA01013232A (ru)
NO (1) NO20016252L (ru)
NZ (1) NZ517058A (ru)
PL (1) PL353855A1 (ru)
SK (1) SK722002A3 (ru)
TR (2) TR200400621T2 (ru)
WO (1) WO2001005820A2 (ru)
ZA (1) ZA200109901B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
CA2331410C (en) * 1998-05-06 2009-07-14 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
MXPA05006521A (es) * 2002-12-20 2005-08-26 Amgen Inc Agentes de enlace que inhiben miostatina.
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
ATE552272T1 (de) 2004-09-30 2012-04-15 Orico Ltd Myostatin-isoform
JP5415071B2 (ja) 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
EP2054434B1 (en) 2006-08-03 2017-03-15 Myostin Therapeutics Pty Ltd Myostatin antagonists
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US20140223592A1 (en) * 2011-07-06 2014-08-07 Pig Myostatin Gene Locus And Uses Thereof Pig myostatin gene locus and uses thereof
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
SI2880053T1 (sl) 2012-08-01 2020-08-31 Ikaika Therapeutics, Llc Blažitev poškodbe tkiva in fibroze s protitelesom proti-LTBP4
IL301607A (en) 2013-05-06 2023-05-01 Scholar Rock Inc Preparations and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
CN113347990A (zh) 2018-12-21 2021-09-03 西北大学 膜联蛋白在预防和治疗肌膜损伤中的用途
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
SI0975668T1 (sl) 1997-04-15 2007-02-28 Pharmexa As Modificirana molekula TNFalfa, DNA, ki kodira tako modificirano molekulo TNFalfa in cepivo, ki vsebuje tako modificirano molekulo TNFalfa in DNA
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
ZA200109901B (en) 2003-05-28
HRP20010900A2 (en) 2003-08-31
EE200200025A (et) 2003-04-15
AU5967500A (en) 2001-02-05
AU778470B2 (en) 2004-12-09
MXPA01013232A (es) 2005-05-24
WO2001005820A2 (en) 2001-01-25
KR20020026544A (ko) 2002-04-10
US7056512B1 (en) 2006-06-06
NZ517058A (en) 2004-04-30
TR200200133T2 (tr) 2002-05-21
SK722002A3 (en) 2003-02-04
HUP0201861A3 (en) 2004-07-28
WO2001005820A3 (en) 2001-07-19
EA005248B1 (ru) 2004-12-30
EP1200119A2 (en) 2002-05-02
KR100750695B1 (ko) 2007-08-22
CN1384757A (zh) 2002-12-11
NO20016252D0 (no) 2001-12-19
TR200400621T2 (tr) 2004-08-23
NO20016252L (no) 2002-03-15
JP2003506325A (ja) 2003-02-18
US7070784B1 (en) 2006-07-04
PL353855A1 (en) 2003-12-01
HK1048937A1 (zh) 2003-04-25
IL146845A0 (en) 2002-07-25
HUP0201861A2 (en) 2002-09-28
CA2379852A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
EA200200182A1 (ru) Способ отрицательной регуляции активности gdf-8
EA200200889A1 (ru) Новый способ супресии амилоида
EA200400332A1 (ru) Новый способ понижающей регуляции амилоида
MXPA02007796A (es) Metodo novedoso para la disminucion de cuerpos amiloides.
RU2422460C2 (ru) Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
JP3328644B2 (ja) 病原性ボレリア・ブルグドルフェリ菌株、病原性ボレリア・ブルグドルフェリの単離及び再培養法
EA200100425A1 (ru) Новые способы терапевтической вакцинации
Migliorini et al. Malaria vaccine: immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity
CN1222936A (zh) 包含疟原虫msp－1的c－末端片段的重组蛋白
NO20051779L (no) Immunisering mot autologt ghrelin
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
CN86100979A (zh) 疟疾疫苗的制备方法
NO20040431L (no) Ny fremgangsmate for nedregulering av amyloid
Wiesmüller et al. The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant.
WO1988002757A1 (en) Hybrid proteins or polypeptides
US20120128706A1 (en) Immune adjuvant comprising atp
CN1053642A (zh) 传染性支气管炎病毒疫苗
YU87201A (sh) Postupak za nishodnu regulaciju gdf-8 aktivnosti
RU2004103468A (ru) Нуклеиновые кислоты, кодирующие рекомбинантный 250 к-да-антиген спорозоитов/мерозоитов eimeria maxima, и их применения
ECSP003580A (es) Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8
EA200500480A1 (ru) Иммунизация против аутологичного грелина
US20090252751A1 (en) Immune adjuvant comprising ubiquinone
EP1502602A3 (en) Methods for therapeutic vaccination
BR102016010178A2 (pt) Chemical products with potential use as antigenic diagnostic markers and / or recombinant vaccines against toxoplasmose formed through the junction of bet epitopes of ama-1, gra-7 and sag-1 proteins of toxoplasma gondii
WO1998018821A1 (en) Vaccines against pathogens characterized by serological cross-reaction but lacking cross-protection

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU